z-logo
open-access-imgOpen Access
Pyrroloquinoline quinone attenuates cachexia-induced muscle atrophy via suppression of reactive oxygen species
Author(s) -
Tongtong Xu,
Xiaoming Yang,
Changyue Wu,
Jiaying Qiu,
Qingqing Fang,
Lingbin Wang,
Shu Yan Yu,
Hualin Sun
Publication year - 2018
Publication title -
journal of thoracic disease
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2018.04.112
Subject(s) - myogenesis , muscle atrophy , cachexia , atrophy , medicine , reactive oxygen species , endocrinology , skeletal muscle , myocyte , myostatin , c2c12 , wasting , chemistry , cancer research , biochemistry , cancer
Cachexia, a wasting syndrome, is most commonly observed in individuals with advanced cancer including lung cancer, esophageal cancer, liver cancer, etc. The characteristic sign of cachexia is muscle atrophy. To date, effective countermeasures have been still deficiency to alleviate muscle atrophy. Reactive oxygen species (ROS) are important regulators of muscle atrophy. Therefore, the effects of a naturally antioxidant, pyrroloquinoline quinone (PQQ), were explored on muscle atrophy induced by cachexia in the present study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom